Proteinase activated receptor 2 (PAR2) modulation of airway smooth muscle function
Black, Kimberly; MacKenzie, Andrew; Dunning, Lynette; Crilly, Anne; McGarvey, Lorcan; Thornbury, Keith; Goodyear, Carl; Lockhart, John; Litherland, Gary
Published in:
Irish Journal of Medical Science
DOI:
10.1007/s11845-018-1898-7
Published: 08/10/2018

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the UWS Academic Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
If you believe that this document breaches copyright please contact pure@uws.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Proteinase activated receptor 2 (PAR2) modulation of airway smooth muscle function

K. Black¹, A. MacKenzie¹, L. Dunning¹, A. Crilly¹, L. McGarvey², K. Thornbury³, C.S. Goodyear⁴, J.C. Lockhart¹, G.J. Litherland¹

¹Border & REgions Airways Training Hub, Centre for Musculoskeletal Science, Institute of Biomedical and Environmental Health Research, School of Health & Life Sciences, University of the West of Scotland, Paisley, Scotland. ²Queens University Belfast. ³Dundalk Institute of Technology. ⁴Institute of Infection, Immunity & Inflammation, University of Glasgow.

Chronic obstructive pulmonary disease (COPD) is a progressive lung condition characterised by airflow obstruction and irreversible lung damage. Hyperactivity and growth of airway smooth muscle (ASM) limit airflow and are key features of COPD. Proteinase activated receptor-2 (PAR2) is a key modulator of inflammatory responses in respiratory disease, such as asthma and promotes ASM relaxation. However, the precise role of the receptor in ASM in conditions such as COPD is not well understood (1). The aim of this study was to establish an ex vivo murine airway myograph assay for investigation of functional PAR2 responses to challenges relevant in COPD pathology.

To achieve this, murine trachea and bronchi tissue was either mounted on a wire myograph for dynamic tension recording or processed for immunohistochemical localisation of PAR2 expression.

PAR2 was present on both murine airway and lung tissue. Stimulation of PAR2 with trypsin (10 U ml⁻¹) or activating peptide was observed to induce relaxation responses in ASM tension.

Taken together this data verifies that PAR2 is present and functional in murine airways, and ex vivo modulation alters ASM tone. Ongoing experiments will investigate the effect of disease-relevant insults on this modulation in wild type and PAR2-deficient airways.